Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Spero Therapeutics (SPRO) Return on Equity (2017 - 2025)

Spero Therapeutics' Return on Equity history spans 9 years, with the latest figure at 0.2% for Q4 2025.

  • For Q4 2025, Return on Equity rose 134.0% year-over-year to 0.2%; the TTM value through Dec 2025 reached 0.2%, up 134.0%, while the annual FY2025 figure was 0.16%, 100.0% up from the prior year.
  • Return on Equity reached 0.2% in Q4 2025 per SPRO's latest filing, up from 1.3% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.3% in Q4 2023 to a low of 2.78% in Q3 2022.
  • Average Return on Equity over 5 years is 0.74%, with a median of 0.69% recorded in 2022.
  • Peak YoY movement for Return on Equity: plummeted -200bps in 2022, then surged 284bps in 2023.
  • A 5-year view of Return on Equity shows it stood at 0.88% in 2021, then increased by 24bps to 0.66% in 2022, then soared by 145bps to 0.3% in 2023, then tumbled by -485bps to 1.14% in 2024, then skyrocketed by 118bps to 0.2% in 2025.
  • Per Business Quant, the three most recent readings for SPRO's Return on Equity are 0.2% (Q4 2025), 1.3% (Q3 2025), and 1.47% (Q2 2025).